140 related articles for article (PubMed ID: 35195913)
1. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares L; Spigel DR; Chen Y; Jove M; Juan-Vidal O; Rich P; Hayes T; Calderón VG; Caro RB; Navarro A; Dowlati A; Zhang B; Moore Y; Yao X; Kokhreidze J; Ponce S; Bunn PA
Cancer; 2022 May; 128(9):1801-1811. PubMed ID: 35195913
[TBL] [Abstract][Full Text] [Related]
2. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
J Clin Oncol; 2024 Apr; ():JCO2302110. PubMed ID: 38648575
[TBL] [Abstract][Full Text] [Related]
3. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
4. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
6. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M; Murakami S; Kawakami H; Okishio K; Tamiya M; Kobayashi H; Fujimoto D; Sugawara S; Kozuki T; Oya Y; Izumi H; Shiroyama T; Satouchi M; Yamamoto N; Kaname S; Matsuoka D; Otake Y; Takase T; Semba T; Azuma K
Cancer Res Commun; 2024 Jan; 4(1):226-235. PubMed ID: 38181055
[TBL] [Abstract][Full Text] [Related]
9. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
Arnold SM; Chansky K; Baggstrom MQ; Thompson MA; Sanborn RE; Villano JL; Waqar SN; Hamm J; Leggas M; Willis M; Rosales J; Crowley JJ
Clin Lung Cancer; 2020 Jul; 21(4):357-364.e7. PubMed ID: 32173247
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Sachdev JC; Munster P; Northfelt DW; Han HS; Ma C; Maxwell F; Wang T; Belanger B; Zhang B; Moore Y; Thiagalingam A; Anders C
Breast Cancer Res Treat; 2021 Feb; 185(3):759-771. PubMed ID: 33201358
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Kim YS; Park SH; Kyung SY; Sym SJ; Lee SP; Park JW; Jung SH; Park J; Cho EK; Lee JH; Shin DB
Med Oncol; 2011 Mar; 28(1):342-50. PubMed ID: 20198458
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
16. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Bandyopadhyay A; Sharma S; Behera D; Singh N
Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Kondo R; Watanabe S; Shoji S; Ichikawa K; Abe T; Baba J; Tanaka J; Tsukada H; Terada M; Sato K; Maruyama Y; Makino M; Hirata A; Tanaka H; Koya T; Yoshizawa H; Kikuchi T
Oncology; 2018; 94(4):223-232. PubMed ID: 29444512
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
